. 2022 Jun 24;23(13):7027. doi: 10.3390/ijms23137027

Table 1.

Summary of PTP1B inhibitors (undergone/undergoing clinical trials).

Compound	Company	IC₅₀ or K_i (µM)		Clinical Phase	Continued or Not	Indications	Trials’ Registration Number
Compound	Company	PTP1B	TCPTP	Clinical Phase	Continued or Not	Indications	Trials’ Registration Number
Ertiprotafib	Pfizer	IC₅₀ > 20	Unknown	Phase II	×	T2DM	Unknown
JTT-551	Tobacco	K_i = 0.22	K_i = 9.30	Pre-clinical	×	T2DM, obesity	Unknown
KQ-791	Kaneq Bioscience	Unknown	Unknown	Phase I	Unknown	T2DM	ClinicalTrials.gov: NCT02445911
TTP-814	TransTech Pharma	Unknown	Unknown	Phase II	×	T2DM	Unknown
Trodusquemine	DepYmed	IC₅₀ = 1.0	IC₅₀ = 224	Phase I	×	T2DM, obesity Metastatic breast cancer	ClinicalTrials.gov: NCT00606112 ClinicalTrials.gov: NCT02524951
DPM-1001	DepYmed	IC₅₀ = 0.10	Unknown	Pre-clinical	√	T2DM, obesity	Unknown
IONIS 113715	IONIS Pharmaceuticals	IC₅₀ < 0.01	Unknown	Phase II	×	T2DM	ClinicalTrials.gov: NCT00330330
IONIS PTP1BRx	IONIS Pharmaceuticals	Unknown	Unknown	Phase II	√	T2DM	ClinicalTrials.gov: NCT01918865